Umbilical cord-derived mesenchymal stem cells promote myeloid-derived suppressor cell enrichment by secreting CXCL1 to prevent graft-versus-host disease after hematopoietic stem cell transplantation |
| |
| Institution: | 1. Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Third Military Medical University (Army Medical University), Chongqing, China;2. Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, California, USA;3. Department of Cell Biology, College of Basic Medicine, Third Military Medical University (Army Medical University), Chongqing, China;1. Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, 6825 Boulevard LaSalle, Verdun, Montreal, QC H4H 1R3, Canada;2. Alzheimer''s Disease Research Unit, Douglas Hospital, McGill University, Montreal, Canada;3. Department of Neurology, National Neuroscience Institute, Singapore;4. Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium;5. McConnell Brain Imaging Centre, McGill University, 3801 University Street, Montreal, Québec H3A 2B4, Canada;6. Montreal Neurological Institute, 3801 University Street, Montreal, Québec H3A 2B4, Canada;7. Department of Neurology and Neurosurgery, McGill University, 3801 University Street, Montreal, Québec H3A 2B4, Canada;1. Cumming School of Medicine, University of Calgary, Calgary, Canada;2. Alberta Health Services, Calgary, Canada;3. Alberta Precision Laboratories, Calgary, Canada;1. Department of Hematology, Complejo Hospitalario Universitario, Granada, Spain;2. Genyo Pfizer, Universidad de Granada, Junta de Andalucía, Centre for Genomics and Oncological Research (GENYO), Granada, Spain;3. Cellular manufacturing Unit, Instituto de Investigación Biosanitaria (IBS), Complejo Hospitalario Universitario, Granada, Spain;4. Department of Hematology, Hospital Clínico, Valencia, Spain;5. Department of Immunology, Complejo Hospitalario Universitario, Granada, Spain;6. Department of Hematology, Hospital General, Jerez, Spain;7. Department of Hematology, Hospital Carlos Haya, Málaga, Spain;8. Department of Hematology, Hospital Virgen del Rocío, Sevilla, Spain;9. School of Medicine, University of Valencia, Spain;1. Cardiology Department, Santa Cruz Hospital, West Lisbon Hospital Center, Lisbon, Portugal;2. Hospital da Luz Lisboa, Luz Saúde, Lisbon, Portugal;3. Nova Medical School, Lisbon, Portugal;4. Department of Cardiac Surgery, University Hospital Centre São João, Porto, Portugal;5. Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal;6. Institute for Research and Innovation in Health, University of Porto, Portugal;7. Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Portugal;8. Instituto Nacional de Engenharia Biomédica, University of Porto, Portugal |
| |
| Abstract: | Background aimsHuman mesenchymal stem cells (MSCs) from various tissues have emerged as attractive candidates for the prevention and treatment of graft-versus-host disease (GVHD). However, the molecular machinery that defines and channels the behavior of these cells remains poorly understood.MethodsIn this study, the authors compared the efficacy of four tissue-derived MSC types in controlling GVHD in a murine model and investigated their immunomodulatory effects.ResultsHuman umbilical cord-derived mesenchymal stem cells (hUCMSCs) effectively decreased the incidence and severity of GVHD, which was mediated by the enrichment of myeloid-derived suppressor cells in GVHD target tissues. RNA sequencing results showed that hUCMSCs highly expressed CXCL1.ConclusionsThese results suggest a novel prophylactic application of hUCMSCs for controlling GVHD after allogeneic hematopoietic stem cell transplantation. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
